Amgen gains after strong quarterly results and continued product momentum

Amgen's shares rose by approximately 4% after the biotechnology company reported strong second-quarter 2026 results that exceeded Wall Street expectations. The company achieved adjusted earnings per share of $6.29 and revenue of $10.05 billion, driven by a 10% year-over-year increase in total revenue and growth across its product portfolio, with 22 products showing double-digit sales growth. CEO Robert Bradway highlighted the strong performance of key growth drivers and confidence in sustained growth for the next decade.